Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

High-Tech Blood Test Predicts Premature Birth Risk

By Labmedica International staff writers
Posted on 27 Feb 2013
A blood test that predicts preterm birth harvests exosomes from a blood sample and looks for a specific biomarker fingerprint that indicates a high risk for preterm birth, even in women with no known risk factors.

NX PharmaGen (Louisville, KT, USA) has conducted early studies with maternal serum samples using its NeXosome Preterm Birth Assay. Two cohorts were balanced for age and subjects were asymptomatic with no known risk factors, such as hypertension, twins, or gestational diabetes. The average age was 28. In the study, a preterm birth was before 34 weeks and after 37 weeks was full-term.

As early as 15 weeks, the test could detect a risk for preterm birth. NX PharmaGen’s initial human studies also suggest the test could be used for early detection, sub-typing/staging, drug receptor presence/absence, and recurrence monitoring for cancer, including lung cancer, ovarian cancer, and brain cancer.

“If you harvest exosomes and open them up and look at their content, the protein content of a term pregnancy looks very different from a preterm pregnancy,” commented Brian Brohman, co-founder and chief business officer of NX Pharmagen.

The initial benefit of the NeXosome Preterm Birth Assay will allow doctors to move a patient from normal OBGYN care to a fetal medicine specialist.

“This is a tool to tell doctors where they should be spending extra time,” Brian Brohman said. “If you can extend the pregnancy on knowledge of a risk, you can save lots of money.”

Next steps for NX PharmaGen are assay optimization and validation. Brian Brohman said that it is too early to know which regulatory path the company will take: Clinical Laboratory Improvement Amendments a laboratory-developed test (CLIA LDT) and an US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval.

The company is seeking patents on the biomarker pattern that indicates a high risk of premature birth and the method of harvesting exosomes from a blood sample.

Related Links:

NX PharmaGen




DiagCor Bioscience
Sekisui Diagnostics
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.